Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure.
CD4 T helper (Th) cells are reported to be essential for initiating and maintaining an effective immune response to hepatitis B virus (HBV) infection. Th9 cells are a new subset of CD4 Th cells that produce interleukin (IL)-9 and IL-10. The present study aimed to investigate the percentage of Th9 cells relative to the number of CD4 cells in peripheral blood. We also measured serum IL-9 and IL-10 levels in different stages of HBV infection and their relationship with progress and prognosis of liver disease. Whole blood samples from 111 patients with HBV infection, including 39 chronic hepatitis B (CHB), 25 HBV-liver cirrhosis (HBV-LC), 21 acute-on-chronic liver failure (ACLF) patients, and 26 healthy controls were collected. The percentage of Th9 cells and serum IL-9 and IL-10 levels were determined. There was no significant difference in the percentage of Th9 cells and serum IL-9 and IL-10 levels among different groups, nor were these related to hepatitis B e antigen status, complications of cirrhosis, inflammation index, or prognosis indexes. There was no change in the percentage of Th9 cells before and after antiviral treatment in CHB patients. There was no correlation of Th9 cells with survival of ACLF patients. However, IL-9 and IL-10 levels were significantly higher in the nonsurvived ACLF patients compared to survived ACLF patients. Furthermore, baseline IL-9 level predicted the prognosis of ACLF patients with 87.5% sensitivity and 61.5% specificity.Thus, our data indicate that Th9 cells were unlikely involved in the pathogenesis of HBV infection, but elevation in IL-9 and IL-10 may signal poor prognosis for ACLF.
From the Department of Infectious Diseases and Clinical Laboratory (XY, YZ, JL, RG, MS, DM, ZL, ZS), the First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou; Department of Infectious Diseases (YD), the Second People's Hospital of Pingxiang, Pingxiang; and Department of Infectious Diseases (XY, JZ), Huashan Hospital, Fudan University, Shanghai, China.
Xueping
X
Yu
Yijuan
Y
Zheng
Yong
Y
Deng
Julan
J
Li
Ruyi
R
Guo
Milong
M
Su
Desong
D
Ming
Zhenzhong
Z
Lin
Jiming
J
Zhang
Zhijun
Z
Su
D065290:Acute-On-Chronic Liver Failure / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D002478:Cells, Cultured; D002681:China / Q000453:epidemiology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006515:Hepatitis B virus / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000150:complications / Q000821:virology; D006801:Humans; D007111:Immunity, Cellular; D016753:Interleukin-10; D016906:Interleukin-9 / Q000097:blood*; D008099:Liver / Q000473:pathology*; D008297:Male; D009017:Morbidity / Q000639:trends; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
C508609:IL10 protein, human; C508607:IL9 protein, human; D016906:Interleukin-9; D016753:Interleukin-10